Screener
Arcus Biosciences RCUS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock ($— and $14 from a related party) | — | 142 |
| Proceeds from debt issuances, net | — | 49 |
| Proceeds from issuance of common stock pursuant to equity award plans | 19 | 3 |
| Net cash provided by financing activities | 19 | 194 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | (72) | 98 |
| Cash, cash equivalents and restricted cash at beginning of period | 225 | 153 |
| Cash, cash equivalents and restricted cash at end of period | $153 | $251 |
Item 1. Financial Statements
FAQ
- What is Arcus Biosciences's net change in cash?
- Arcus Biosciences (RCUS) reported net change in cash of -$51M in Q2 2026.
- How has Arcus Biosciences's net change in cash changed year-over-year?
- Arcus Biosciences's net change in cash decreased by 191.1% year-over-year, from $56M to -$51M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Arcus Biosciences's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude